Hengrui Pharma(SH:600276) Di Yi Cai Jing·2025-11-13 09:54Core Viewpoint - The development trajectory of Hengrui Medicine has shown a clear response to market skepticism from four years ago, with significant achievements in recent years, including record-breaking performance and major international contracts [1] Group 1: Company Achievements - Hengrui Medicine has completed a V-shaped recovery, with its half-year report setting a historical record [1] - The company signed a $12 billion overseas contract, marking a significant milestone in its global expansion efforts [1] - Hengrui successfully listed on the Hong Kong Stock Exchange, raising over HKD 10 billion [1] Group 2: Strategic Developments - The Shanghai Innovation Research and Development Center was officially launched at the end of October, representing a key achievement in Hengrui's global strategy [1] - This center signifies a strong collaboration between Shanghai and leading domestic innovative enterprises, enhancing Hengrui's position in the global biopharmaceutical industry [1] Group 3: Future Outlook - The company is positioned to evolve amidst increasing competition in the global biopharmaceutical sector, raising questions about its potential to become a global pharmaceutical giant [1]